Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.

Abstract

To improve the antimyeloma effect of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation in multiple myeloma, we investigated in a phase 1/2 study the effect of low-dose thalidomide (100 mg) followed by DLI in 18 patients with progressive disease or residual disease and prior ineffective DLI after allografting. The overall response rate was 67%, including 22% complete remission. Major toxicity of thalidomide was weakness grade I/II (68%) and peripheral neuropathy grade I/II (28%). Only 2 patients experienced mild grade I acute graft versus host disease (aGvHD) of the skin, while no grades II to IV aGvHD was seen. De novo limited chronic GvHD (cGvHD) was seen in 2 patients (11%). The 2-year estimated overall and progression-free survival were 100% and 84%, respectively. Adoptive immunotherapy with low-dose thalidomide and DLI induces a strong antimyeloma effect with low incidence of graft versus host disease.

• Authors: Nicolaus Kröger, Avichai Shimoni, Maria Zagrivnaja, Francis Ayuk, Michael Lioznov, Heike Schieder, Helmut Renges, Boris Fehse, Tatjana Zabelina, Arnon Nagler, Axel R Zander
• Journal: Blood (Blood) Vol. 104 Issue 10 Pg. 3361-3 (Nov 15 2004) ISSN: 0006-4971 [Print] United States
• PMID: 15292062 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Immunosuppressive Agents
• Thalidomide

Topics

• Adult
• Combined Modality Therapy
• Graft vs Host Disease (epidemiology)
• Hematopoietic Stem Cell Transplantation
• Humans
• Immunosuppressive Agents (administration & dosage, adverse effects)
• Immunotherapy, Adoptive
• Incidence
• Middle Aged
• Multiple Myeloma (drug therapy)
• Remission Induction
• Thalidomide (administration & dosage, adverse effects)
• Transplantation, Homologous
• Treatment Outcome